DDInter1055 DDInter36
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Levofloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Gatifloxacin
Gatifloxacin {u} may lead to a major life threatening interaction when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Enoxacin {u} may lead to a major life threatening interaction when taken with {v} Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Warfarin
Warfarin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Lomefloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin {u} (Compound) resembles {v} (Compound) Moxifloxacin
Moxifloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Acarbose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Albiglutide
Levofloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Levofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may lead to a major life threatening interaction when taken with Albiglutide
Levofloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Warfarin (Compound) and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Levofloxacin (Compound) resembles Moxifloxacin (Compound) and Moxifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide